Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-06

Study Completion Date

2019-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Brazil, sertraline is currently available as film coated tablets for oral administration containing sertraline hydrochloride equivalent to 50 mg or 100 mg sertraline.

The sponsor has developed an oral solution formulation containing 20 mg/mL of sertraline, which must be diluted with 120 mL of water, ginger ale, lime/lemon soda or orange juice to be palatable before use. The purpose of this study is to evaluate the relative bioavailability of Zoloft oral solution compared to Zoloft tablets in healthy participants under fasted conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg

NCT00648856

Healthy

COMPLETED PHASE1

Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects

NCT01699724

Healthy

COMPLETED PHASE1

Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions

NCT00946036

Healthy

COMPLETED PHASE1

A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions

NCT00864019

Healthy

COMPLETED PHASE1

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

NCT00778973

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zoloft Oral Solution

50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.

Group Type EXPERIMENTAL

Zoloft Oral Solution

Intervention Type DRUG

Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water

Zoloft Tablets

Zoloft 50 mg tablet.

Group Type ACTIVE_COMPARATOR

Zoloft tablets

Intervention Type DRUG

Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zoloft Oral Solution

Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water

Intervention Type DRUG

Zoloft tablets

Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female research subjects and/or male research subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
* Female research subjects of non-childbearing potential
* Body mass index (BMI) of 18.5 kg/m2 to 24.9 kg/m2, and a total body weight \>50 kg (\>110 lbs).
* Evidence of a personally signed and dated informed consent document indicating that the research subject has been informed of all pertinent aspects of the study.
* Research subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
* Clinically significant infections within the past 3 months, evidence of any infection within the past 7 days, history of disseminated herpes simplex infection or recurrent (\>1 episode) or disseminated herpes zoster.
* Evidence or history of cyclic neutropenia.
* Personal or family history of hereditary immunodeficiency (eg, severe combined immunodeficiency disorder \[SCID\], Wiskott Aldrich syndrome, X linked agammaglobulinemia).
* Vaccination with live or attenuated vaccines within 6 weeks prior to dosing, or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks following discontinuation of dosing.
* Any condition possibly affecting drug absorption (eg, gastrectomy, colon resection, etc.).
* Research subjects with a history of, or current evidence for, severe gastrointestinal narrowing (pathologic or iatrogenic).
* History of or current positive results for any of the following serological tests: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), anti hepatitis C core antibody (HCV Ab), or human immunodeficiency virus (HIV) 1 and 2.
* A positive urine drug test.
* A positive alcohol screen.
* History of regular alcohol consumption exceeding 14 drinks/week for female research subjects or 21 drinks/week for male research subjects \[1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor\] within 6 months before screening.
* Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. For chewing tobacco, one chew is equivalent to approximately 2 3 cigarettes, so research subjects would be limited to 2 or less chews per day.
* Treatment with an investigational drug within 6 months or 5 half lives preceding the first dose of investigational product (whichever is longer).
* Pregnant female research subjects, breastfeeding female research subjects, fertile male research subjects and female research subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol from at least 14 days prior to the first dose of investigational product until at least 28 days after the last dose of investigational product.
* A positive beta human chorionic gonadotropin test for women of childbearing potential.
* Use of prescription or nonprescription drugs and dietary supplements within 14 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
* Herbal supplements, hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone releasing intrauterine devices \[IUDs\], vaginal ring, and postcoital contraceptive methods), and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of investigational product.
* Depo Provera must have been discontinued at least 6 months prior to the first dose of investigational product.
* Consumption of grapefruit or grapefruit related citrus fruits (eg, Seville oranges, pomelos) or juices within 7 days prior to dosing.
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 3 months prior to screening.
* History of sensitivity to heparin or heparin induced thrombocytopenia.
* History of hypersensitivity to sertraline or any of the components in the formulation of the study products.
* Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol.
* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the research subject inappropriate for entry into this study.
* Research subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or research subjects who are the sponsor's employees, including their family members, directly involved in the conduct of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes